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This scientific commentary refers to “c-Myc-miR-29c-REV3L signaling pathway 
drives the acquisition of temozolomide resistance in glioblastoma” by Luo et al. 
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The emergence of tumour cell resistance to chemotherapy represents a major 
challenge for the development of durable therapeutic strategies across most solid 
cancers including glioblastoma, the most malignant primary brain tumour in adults. 
The standard of care for glioblastoma is maximum surgery as safely feasible followed 
by radiotherapy, with concomitant and maintenance chemotherapy with the alkylating 
agent temozolomide (TMZ/RT→TMZ). This results in a median overall survival in the 
range of 12 months on a population level (Weller et al., 2014). Radiotherapy alone 
doubled median survival in early studies, but the best radiological response is 
commonly stable disease, progression is inevitable, and the efficacy of radiotherapy 
may be partly related to anti-angiogenic rather than intrinsic tumour cell cytotoxic 
effects. Mechanisms underlying resistance to radiotherapy remain poorly understood, 
but extensive hypoxia may be an important factor. 
 
TMZ was approved for the treatment of newly diagnosed glioblastoma because of a 
moderate prolongation of median survival (Stupp et al., 2005). Subgroup analyses 
revealed that the benefit from TMZ was largely restricted to patients with 
glioblastomas that exhibit a particular epigenetic alteration, promoter methylation of 
the O6-methylguanine DNA methyltransferase (MGMT) gene (Hegi et al., 2005). 
However, even these patients eventually all progress and succumb to their disease, 
in the absence of changes in MGMT promoter methylation (Felsberg et al., 2011), 
indicating that novel pathways must be activated to escape from alkylating agent 
chemotherapy. 
 
Considerable efforts have been made to understand and overcome glioma cell 
resistance to chemotherapy, focusing on several proteins and pathways involved in 
cell survival and resistance, including the mismatch repair pathway (MMR) pathway. 
In this issue of Brain, Luo and co-workers report that a c-Myc driven down-regulation 
of microRNA (miR)-29c promotes a TMZ-resistant phenotype of glioma cells that is 
mediated by increased REV3L expression and consequent enhanced DNA repair 
capacity (Luo et al., 2015).  
 
MicroRNAs have been studied extensively over the last decade for their role in 
diverse biological processes, especially in cell proliferation and cell death. These 
small non-coding RNA molecules can affect post-transcriptional control of gene 
expression and may thereby help to regulate several aspects of tumourigenesis, 
including invasiveness, DNA repair, and acquired resistance to genotoxic cancer 
therapy. MicroRNAs can function as either tumour suppressors or promoters, in a 
context-dependent manner. While down-regulation of miR-29c has been associated 
with tumourigenesis and invasiveness in a variety of cancers, including gliomas (Fan 
et al., 2013; Wang et al., 2013), no link to TMZ resistance has been established so 
far. 
 
Here, Luo and co-workers used qPCR and in situ hybridization to confirm a down-
regulation of miR-29c – which was selected from an array-based analysis of matched 
primary and recurrent human gliomas considered TMZ-resistant – in recurrent 
tumour samples and cell lines selected for TMZ resistance (U251/TMZR, 
U87/TMZR). Restoration of miR-29c expression restored TMZ sensitivity. By 
contrast, inhibition of miR-29c in A172 cells, which express high levels of miR-29c 
comparable to those of normal human astrocytes, conferred TMZ resistance. These 
effects were reproduced in an in vivo model of non-obese diabetic (NOD)-severe 
combined immunodeficiency (SCID) mice injected subcutaneously with resistant 
U251/TMZR cells. Prolonged survival was noted in animals treated with 
intraperitoneal TMZ at 20 mg/kg and simultaneous intratumoural injection of miR-29c 
(1 nmol), applied as cholesterol-conjugated 2’-O-methylmodified miR-29c for better 
pharmacokinetic properties. 
 
To assess potential target genes that could be mediating the effect of miR-29c, Luo 
et al. used a somewhat artificial or at least unconventional approach: they generated 
a list of candidate genes that were (i) deregulated in TMZ-resistant cell lines that had 
been engineered to overexpress miR-29c and, (ii) also predicted targets of miR-29c 
according to public databases. They identified REV3L, a DNA repair polymerase 
previously linked to TMZ resistance (Roos et al., 2009), as less strongly expressed in 
the resistant cells with ectopic miR-29c expression; accordingly, inhibition of miR-29c  
by commercially available antisense miR-29c molecules in A172 cells led to an 
increase in REV3L levels. A luciferase reporter assay confirmed direct targeting of 
the 3’UTR on the REV3L mRNA by miR-29c. 
 
In an intracranial mouse model consisting of animals injected with primary GBM-2 or 
GBM-4 glioblastoma cells, prior transfection of the tumour cells with miR-29c-mimics 
reduced REV3L levels determined by immunohistochemistry, reduced tumour burden 
and increased survival when the mice were treated with TMZ. Moreover, when short 
hairpin (sh)REV3L was used to block REV3L expression in resistant GBM-2 and 
GBM-4 cells expressing anti-miR-29c, a sensitizing effect to TMZ was noted. This 
was shown in vitro by decreased colony formation ability and increased apoptosis, 
and in vivo by reduced tumour volume. The most likely mechanism by which REV3L 
overexpression produces TMZ resistance is through sustained DNA repair, since 
U87 scramble-transduced cells showed more rapid DNA repair than U87 cells with 
miR-29c overexpression or REV3L gene silencing. These cells exhibited increased 
levels of γ-H2AX foci, a reaction to DNA double-strand breaks, and chromosomal 
breakage in response to TMZ.  
 
Lastly, the authors identify c-Myc, a transcription factor involved in cell cycle 
progression and apoptosis that is often constitutively expressed in cancer cells, as an 
important positive up-stream regulator of the newly described miR-29c/REV3L axis, 
acting as an miR-29c suppressor and thus indirect REV3L inducer. Taken together, 
therefore, Luo et al. propose a signalling axis whereby TMZ resistance mediated by 
improved DNA repair is achieved through c-Myc-induced suppression of miR-29c 
with consecutive REV3L induction (Fig. 1). The clinical relevance of these findings 
was underlined by a Kaplan-Meier survival analysis of 138 glioblastoma patients 
treated according to standard of care (TMZ/RT→TMZ). Patients with higher miR-29c 
levels reportedly had better survival rates. Of note, the tissue specimens with high 
miR-29c expression had lower levels of c-Myc and REV3L, as predicted from the in 
vitro findings. 
 
This study has some limitations, including the use of a subcutaneous rather than 
intracranial tumour model in some experiments, the artificial approach to identifying 
REV3L as a target of miR-29c, and the lack of cross-resistance to explore whether 
this pathway is specific to TMZ or is relevant for other alkylators such as CCNU, too, 
or for drugs with different modes of action, or even for radiotherapy. 
 
Importantly, the regulation of TMZ resistance reported here was observed in primary 
glioblastoma cells with or without MGMT expression. Accordingly, no regulation of 
MGMT levels was observed when cells were exposed to miR-29c mimics or 
inhibitors. Moreover, no role was identified for the MMR pathway in this resistance 
either. Thus, the interaction of miR-29c and REV3L could represent an interesting 
therapeutic target for all glioblastomas, with or without MGMT promoter methylation, 
provided that this network can be selectively targeted in neoplastic cells. 
 
Future studies should explore which factors regulate c-Myc expression upstream of 
this resistance pathway. Knowledge of this upstream mechanism and factors 
modulating the downstream cascade would allow for potential therapeutic 
interventions, focusing for example on clinically applicable microRNA mimics or 
REV3L inhibitors.  
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Figure legend 
 
Figure 1. Proposed mechanism of TMZ resistance in glioblastoma.  
Up-regulation of the miR-29c suppressor c-Myc leads to increased expression of 
REV3L, resulting in enhanced DNA repair and chemoresistance. Potential 
approaches to counteract this pathway are indicated on the right. 
 
 
Glossary 
 
MGMT - O6 methylguanine DNA methyltransferase – DNA repair protein repairing 
O6MeG lesions induced by alkylating drugs, expressed in normal cells as well as 
tumour cells with an unmethylated MGMT promoter; serves as a predictive factor for 
benefit from temozolomide in glioblastoma. 
 
MicroRNA – small, non-coding RNA molecules that bind to complementary 
sequences of mRNA, thereby promoting mRNA degradation or inhibition of mRNA 
translation. 
 
MYC – transcription factor involved in many biological processes including cell death 
and proliferation, mainly by up-regulation of gene expression; frequently amplified in 
several cancer types.  
 
REV3L – protein reversionless 3-like – subunit of a DNA polymerase relevant for 
DNA repair; overexpression has been linked to mutagenesis and drug resistance. 
 
Temozolomide – alkylating oral chemotherapeutic agent used as first-line therapy in 
glioblastoma. 
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